Almost 70% of Exchange-Held Copper Now Sits in the

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
49
Almost 70% of Exchange-Held Copper Now Sits in the US



The United States consumes roughly 6% of global copper, yet now holds nearly 70% of the copper stored across major global futures exchanges: the London Metal Exchange, COMEX, and the Shanghai Futures Exchange. Ole Hansen, Saxo Bank’s Head of Commodity Strategy, argues that this unusual concentration is largely driven by expectations of America imposing tariffs on imported refined copper.

Traders have been moving copper into the U.S. ahead of a possible tariff because metal already inside the country could become more valuable if duties are introduced. This comes after the U.S. Commerce Department proposed gradually increasing tariffs, although the final decision remains pending.

At the same time, strong Chinese demand, particularly from the country’s expanding energy-transition industries, is keeping pressure on copper supplies elsewhere. The result is a growing imbalance between the U.S. and other markets.

Hansen warns that some of the copper shipped into America could remain there for an extended period. This would effectively reduce the amount of metal available to other regions and contribute to tighter global supplies.

The LME has also shown signs of short-term physical tightness. Copper for immediate delivery recently traded significantly above the three-month contract, creating a steep backwardation. However, Hansen believes this does not necessarily signal a massive shortage.

Much of the price difference may be linked to traders covering positions ahead of the delivery period rather than a shortage involving millions of tons.

Longer term, increasing copper supply remains difficult. Mining companies face declining ore grades, higher energy and production costs, and long development periods for new mines. One of the leading producers of copper globally, Chile, is experiencing weaker output. Building new mines is expensive and can take years, making rapid increases in supply difficult even when prices are high.

The copper situation contrasts with gold and silver. Copper is facing physical scarcity because it is heavily consumed by industry, including energy infrastructure and technology. Gold, by comparison, is increasingly being accumulated as a financial and monetary asset, particularly by central banks and investors seeking protection against economic and debt-related risks.

Hansen remains bullish on gold if economic uncertainty, debt concerns and geopolitical risks persist, while he is more cautious about silver at elevated prices because of its strong dependence on industrial demand. Overall, the copper market is being shaped by a combination of tariff expectations, strong Asian demand, limited mine expansion and the unusual concentration of inventories in the United States.

Unless the tariff threat fades or American copper begins flowing back into global markets, supplies outside the U.S. could remain tight.

For entities like New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) focused on exploring for and developing silver resources, the current macroeconomic and geopolitical picture around the world could draw more interest as investors seek to diversify their holdings.

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer 

New Pacific Metals Corp. (NEWP) Stock Research Links

NEWP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 313

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 193

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 128

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 224

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Phreesia Announces Q3 Fiscal Year 2025 Financial Results

Updated Category News Views 71

Phreesia to Release Fiscal Q3 2025 Results Soon Phreesia, Inc. (NYSE: PHR) has great news for its stakeholders! The company revealed plans to announce its financial results for the third quarter of fiscal year 2025 right after market closing on a Monday in December. During this quarter, the firm experienced substantial growth and is eager to share the details with the...

Continue Reading
Innovative Water Bowl Design Enhances Pet Hydration Experience

Updated Category News Views 374

Revolutionary Pet Water Bowl Crafted for Optimal Hydration Every pet owner knows the importance of keeping their furry friends hydrated, especially during hot days. A new invention promises to enhance the experience for pets and their owners alike. This innovative water bowl, known as the THERMA DRINK, is designed with features that cater directly to pet needs. The idea...

Continue Reading
HPH's Leadership Changes Signify Strategic Direction Ahead

Updated Category News Views 177

Leadership Transitions at HPH Highest Performances Holdings Inc. (NASDAQ: HPH) has recently seen a notable change in its Board of Directors. The company announced that Mr. Peh Chin Hua's tenure as Director has come to an end, effective immediately. This decision is part of a broader strategy aimed at strengthening the Board's overall composition and capabilities. Current...

Continue Reading
Apranga Group Reports Growth in Retail Turnover for 2025

Updated Category News Views 132

Apranga Group Retail Performance Overview for 2025 Apranga Group, a major player in the retail sector, has announced its impressive financial performance for the first six months of 2025, demonstrating notable growth compared to the prior year. The company's retail turnover reached a commendable EUR 166.1 million, reflecting a 2.8% increase from the same period in 2024....

Continue Reading
IMUNON Unveils Promising New Vaccine Data for COVID-19

Updated Category News Views 154

New Vaccine Insights from IMUNON's Phase 1 Clinical Trial The innovative PlaCCine technology platform developed by IMUNON, Inc. (NASDAQ: IMNN) promises remarkable durability and advantages over traditional mRNA vaccines, particularly in the struggle against COVID-19. Robust Results from IMNN-101 Vaccine Trials In an encouraging announcement, IMUNON shared pivotal data...

Continue Reading